Figure 7.

The −16kb enhancer of Fgf23 mediates the inflammation‐induced increase in circulating intact FGF23 levels. Eight‐ to 12‐week‐old wild‐type (WT) and Fgf23 ^−16KO mice were injected with 10 mg/kg of LPS (female mice) (A), 2 μg of recombinant TNFα (female mice) (B), 50 ng/g of IL‐1β (male mice) (C), or vehicle. Cardiac blood was collected at time of death, which was 6 hours after LPS and IL‐1β injection and 3 hours after TNFα injection. Circulating intact FGF23 (iFGF23) levels were measured by ELISA. The bars represent the mean ± SD of 4 to 9 mice/group. Statistical comparisons were performed using two‐way ANOVA with multiple comparison test using the Benjamini‐Hochberg procedure. *p < 0.05 effect of treatment within the same genotype; #p < 0.05 effect of genotype within the same treatment and “a”, p < 0.05 magnitude of the difference (vehicle injection) is less in Fgf23 ^−16KO mice compared with WT mice.